Resiniferatoxin

Phase 3Small molecule

SSorrento Therapeutics, Inc.

Resiniferatoxin is one of 85 small molecule programs targeting Bone pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone PainActive, not recruiting

Cancer PainActive, not recruiting

OsteoarthritisActive, not recruiting

NeuromaActive, not recruiting

Bone PainPhase 1/Phase 2

Active, not recruiting

Cancer PainPhase 3

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

NeuromaPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Resiniferatoxin

SSorrento Therapeutics, Inc.

Phase 3

4 2

Ilaris

Novartis

Preclinical

2 3

Platelet Rich Plasma

ZZagazig University

Preclinical

25 4

Bayer Aspirin

Glucophage

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Benadryl

Naproxen Sodium

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

Ansaid

PPharmacia and Upjohn

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Neuroma

NCT05695339

Phase 1/2Not yet recruiting

Bone Pain

NCT02522611

Clinical

Trials by Indication[1]

Osteoarthritis4 trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee

Withdrawn·SSorrento Therapeutics, Inc.·Phase 3·NCT04044742

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Unknown status·SSorrento Therapeutics, Inc.·Phase 2·NCT04885972·124 enrolled

Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

Withdrawn·SSorrento Therapeutics, Inc.·Phase 3·NCT04386980

Show 1 more trial

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

Completed·SSorrento Therapeutics, Inc.·Phase 1·NCT03542838·94 enrolled

Cancer Pain2 trials

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Withdrawn·SSorrento Therapeutics, Inc.·Phase 3·NCT04572776

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

Completed·SSorrento Therapeutics, Inc.·Phase 1·NCT03226574·17 enrolled

Advanced Cancer1 trial

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Suspended·SSorrento Therapeutics, Inc.·Phase 2·NCT05067257·120 enrolled

Neuroma1 trial

Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain

Recruiting·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT05695339·24 enrolled

Bone pain1 trial

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

Not yet recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1/2·NCT02522611·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Resiniferatoxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Resiniferatoxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Resiniferatoxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sorrento Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSorrento Therapeutics, Inc.

Resiniferatoxin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Osteoarthritis4 trials

Cancer Pain2 trials

Advanced Cancer1 trial

Neuroma1 trial

Bone pain1 trial

References

Drug Info

Quick Facts

Related News